The company has entered into an exclusive global licensing agreement with Saniona to develop and commercialize SAN2355, a novel, highly selective preclinical compound for epilepsy and other potential indications. The company will lead and fund all future development and regulatory efforts for the asset, which is designed to overcome the limitations of existing therapies. This move expands the company's pipeline in neuroscience.